Revvity initiated with Outperform, $145 target at Raymond James

Raymond James initiated coverage of Revvity with an Outperform rating and $145 price target. The company has a “substantial” reoccurring revenue mix with a number one position in its primary markets, the analyst tells investors in a research note. During “these more challenging times,” the analyst expects quality and market cap size too offer “important relative comfort” in the life science tools sector.